Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02383927
Recruitment Status : Recruiting
First Posted : March 10, 2015
Last Update Posted : May 9, 2019
Sponsor:
Information provided by (Responsible Party):
Kura Oncology, Inc.

Brief Summary:
Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available. Note; Only cohort 2 (Head & Neck SCC) and cohort 3 (Other SCC) are currently open

Condition or disease Intervention/treatment Phase
Thyroid Cancer Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) HRAS Mutant Tumor Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor Drug: Tipifarnib Phase 2

Detailed Description:

This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with locally advanced, unresectable or metastatic, relapsed and/or refractory tumors that carry HRAS mutations and for whom there is no curative therapy available. Subjects with information available on tumor HRAS status previously generated are eligible. All subjects must consent to provide at least 10 tumor slides from a prior diagnostic biopsy for a retrospective testing of HRAS gene status at a central facility.

Subjects will be enrolled into three nonrandomized cohorts:

  • Cohort 1: Malignant thyroid tumors with HRAS mutations (cohort is closed).
  • Cohort 2: Squamous Cell Carcinoma Head and Neck Cancer with HRAS mutations.
  • Cohort 3: Squamous Cell Carcinoma (SCC) with HRAS mutations other than HNSCC

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations
Study Start Date : March 2015
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : October 2020

Arm Intervention/treatment
Experimental: Cohort 1
Thyroid Cancer
Drug: Tipifarnib
FTase inhibitor
Other Name: Zarnestra

Experimental: Cohort 2
Squamous Head and Neck Cancer
Drug: Tipifarnib
FTase inhibitor
Other Name: Zarnestra




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 24 months (approx. 12 months accrual + 12 months follow up) ]

Secondary Outcome Measures :
  1. Progression-free Survival (PFS) [ Time Frame: 24 months (approx. 12 months accrual + 12 months follow up) ]
  2. Duration of Response (DOR) [ Time Frame: 24 months (approx. 12 months accrual + 12 months follow up) ]
  3. Number of Subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Until 30 days after the end of study ]
    Number of patients that experience Adverse Events (AEs). Adverse Events (AEs) and Serious Adverse Events (SAEs) will be graded according to the NCI-CTCAE (Version 4.03).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • histologically or cytologically confirmed diagnosis of thyroid cancer (cohort 1: Note: Cohort closed to further enrolment) or Squamous Cell Carcinoma head and neck cancer (cohort 2) or Squamous Cell Carcinoma other than HNSCC (cohort 3) for which there is no curative therapy available.
  • tumor that carries a missense HRAS mutation ith a variant allele frequency (VAF) > 20%.
  • Subject consents to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status
  • Subject has measurable disease according to RECIST v1.1 and has relapsed or is refractory to prior therapy.
  • At least 2 weeks since the last systemic therapy or radiotherapy regimen prior to enrolment
  • ECOG PS 0 or 1
  • Acceptable liver function
  • Acceptable renal function
  • Acceptable hematologic status • Serum albumin ≥ 3.5 g/dL. Subjects with tumors potentially highly sensitive to tipifarnib (HRAS mutant VAF ≥ 35%) may be enrolled despite a serum albumin < 3.5 g/dL.

Exclusion Criteria:

  • Prior treatment with an FTase inhibitor
  • History of relevant coronary heart disease or myocardial infarction within last 3 years, NYHA Grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or serious cardiac arrhythmia requiring medication except atrial fibrillation.
  • Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 4 weeks prior to Cycle 1 Day 1). Controlled brain metastases that require continuous high dose corticosteroid use within 4 weeks of Day 1.
  • Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks first dose
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to first dose, without complete recovery.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02383927


Contacts
Layout table for location contacts
Contact: Jeanne Britt 678-777-0686 medicalaffairs@kuraoncology.com

  Hide Study Locations
Locations
Layout table for location information
United States, California
University of California, Los Angeles Recruiting
Los Angeles, California, United States, 90404
United States, Georgia
Wihship Cancer Institute of Emory University Recruiting
Atlanta, Georgia, United States, 30322
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
United States, Michigan
University of Michigan Comprehensive Cancer Center Recruiting
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55902
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
United States, Oklahoma
Oklahoma University Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111-2497
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Belgium
University Hospital Antwerp Recruiting
Antwerp, Belgium
Cliniques universitaires Saint-Luc Recruiting
Brussels, Belgium
CHU Recruiting
Yvoir, Belgium
France
Insitut Bergonie Not yet recruiting
Bordeaux, France
Centre Léon Bérard Recruiting
Lyon, France
Centre Antoine Lacassagne Not yet recruiting
Nice, France
Institute Gustave Roussy (IGR) Recruiting
Paris, France
Germany
University Hospital Wuerazburg Not yet recruiting
Würzburg, Germany
Greece
Attikon University Hospital Not yet recruiting
Attikí, Greece
Italy
Instituto Nazionale Tumori Recruiting
Milan, Italy
Korea, Republic of
Asan Medical Center Recruiting
Seoul, Korea, Republic of
Samsung Medical Center Recruiting
Seoul, Korea, Republic of
Netherlands
University Medical Center Recruiting
Groningen, Netherlands
Spain
Hospital Vall d' Hebron Recruiting
Barcelona, Spain, 08035
Hospital Clinic de Barcelona Recruiting
Barcelona, Spain
Hospital del Mar Recruiting
Barcelona, Spain
Hospital Universitario Doce de Octubre Recruiting
Madrid, Spain
Hospital Universitario La Paz Recruiting
Madrid, Spain
MD Anderson Cancer Center Madrid Recruiting
Madrid, Spain
START, Centro Integral Oncologico Clara Campal Recruiting
Madrid, Spain
Hospital Universitario Virgen de la Victoria Recruiting
Málaga, Spain
Complejo Hospitalario de Navarro Recruiting
Navarro, Spain
Hospital Universitario Virgen de la Rocio Recruiting
Sevilla, Spain
Hospital Universitario y Politécnico La Fe Recruiting
Valencia, Spain
United Kingdom
Royal Marsden Recruiting
London, England, United Kingdom
University College Hospital Recruiting
London, England, United Kingdom
Sponsors and Collaborators
Kura Oncology, Inc.

Layout table for additonal information
Responsible Party: Kura Oncology, Inc.
ClinicalTrials.gov Identifier: NCT02383927     History of Changes
Other Study ID Numbers: KO-TIP-001
First Posted: March 10, 2015    Key Record Dates
Last Update Posted: May 9, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Tipifarnib
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Thyroid Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Endocrine Gland Neoplasms
Endocrine System Diseases
Thyroid Diseases
Antineoplastic Agents